12 completed, 7 terminated, 2 active not recruiting, 2 unknown. 16 Phase 1, 16 Phase 2, 2 Phase 3, 1 Not applicable.
Follow Transgene: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer BT-001 followed by Pembrolizumab (PD-1 Blocking Antibody) - Rectal Cancer Patients | Phase 1 | Recruiting | Henry Smith | 20 | 2026-10-23 | 2026-11-04 |
| A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) TG6050 - Non-small Cell Lung Cancer | Phase 1 | Terminated | Transgene | 22 | 2023-04-05 | 2025-07-09 |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors BT-001, Pembrolizumab [KEYTRUDA®] - Metastatic Cancer, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Terminated | Transgene | 31 | 2021-02-25 | 2025-11-21 |
| Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer TG6002, Flucytosine (5-FC) - Colorectal Neoplasms | Phase 1 / Phase 2 | Terminated | Transgene | 15 | 2020-01-17 | 2023-06-23 |
| A Clinical Trial Evaluating TG4050 in Head and Neck Cancer TG4050 - Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Active not recruiting | Transgene | 80 | 2019-12-12 | 2026-01-16 |
| A Trial Evaluating TG4050 in Ovarian Carcinoma. TG4050 - Ovarian Carcinoma, Fallopian Tube Cancer | Phase 1 | Completed | Transgene | 64 | 2019-12-09 | 2025-11-14 |
| Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. TG6002, Flucytosine (5-FC, Ancotil) - Colorectal Neoplasm, Digestive System Neoplasm | Phase 1 / Phase 2 | Terminated | Transgene | 51 | 2018-10-16 | 2023-06-23 |
| A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) TG4010, Chemotherapy, Nivolumab - Non Small Cell Lung Cancer Metastatic | Phase 2 | Completed | Transgene | 44 | 2018-01-05 | 2022-01-11 |
| Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®) - Glioblastoma, Brain Cancer | Phase 1 / Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 78 | 2017-10-12 | 2017-11-06 |
| Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers TG4001, Avelumab - HPV-Related Carcinoma, HPV-Related Cervical Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Transgene | 143 | 2017-09-01 | 2026-02-05 |
| A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) Pexastimogene Devacirepvec (Pexa Vec), Nivolumab - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Terminated | Transgene | 14 | 2017-07-27 | 2021-11-19 |
| Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. Pexa-Vec, Ipilimumab - Metastatic Tumor, Advanced Tumor | Phase 1 | Completed | Centre Leon Berard | 22 | 2017-01-03 | 2022-07-25 |
| TG4010 and Nivolumab in Patients With Lung Cancer TG4010, Nivolumab - Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | Phase 2 | Completed | Megan Daly, MD | 13 | 2016-12-14 | 2025-11-10 |
| Safety and Tolerability of TG1050: A Dose-finding Study TG1050, Placebo - Chronic Hepatitis B | Phase 1 | Completed | Transgene | 48 | 2015-10-01 | 2018-11-27 |
| A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) Cyclophosphamide and JX-594 dose escalation, Cyclophosphamide and JX-594, Cyclophosphamide - Solid Tumors, Soft-tissue Sarcoma | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 197 | 2015-09-18 | 2022-02-02 |
| Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection blood draw - Chronic Hepatitis B | Not applicable | Completed | Transgene | 166 | 2014-12-01 | 2016-02-02 |
| Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer TG4010, placebo - Non-Small-Cell Lung Carcinoma | Phase 2 / Phase 3 | Terminated | Transgene | 222 | 2012-04-01 | 2017-01-05 |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma JX-594, Irinotecan - Colorectal Carcinoma, CRC | Phase 1 / Phase 2 | Completed | Jennerex Biotherapeutics | 52 | 2012-01-01 | 2026-08-05 |
| Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients pegylated interferon and ribavirin, TG4040 + SOC - Chronic Hepatitis C Infection | Phase 2 | Completed | Transgene | 140 | 2010-05-01 | 2013-08-13 |
| Trial of TG4023 Combined With Flucytosine in Liver Tumors MVA-FCU1, flucytosine - Hepatocellular Carcinoma | Phase 1 | Completed | Transgene | 16 | 2009-09-01 | 2014-07-16 |
Showing 20 of 24. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Colorectal Neoplasms (4) · Carcinoma, Hepatocellular (2) · Hepatitis B, Chronic (2) · Neoplasm Metastasis (2) · Rectal Neoplasms (2) · Sarcoma (2) · Vaccinia (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Merkel Cell (1) · Colonic Neoplasms (1) · Digestive System Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1)
Flucytosine (4) · Nivolumab (3) · TG4010 (3) · avelumab (2) · Bevacizumab (1) · Blood Specimen Collection (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Drug Therapy (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · Immunotherapy (1) · Ipilimumab (1) · Irinotecan (1)
France (20) · United States (9) · Germany (5) · Belgium (4) · Spain (4) · Canada (3) · Hungary (3) · United Kingdom (3) · Poland (2) · Denmark (1) · Israel (1) · Italy (1) · Switzerland (1)
Derek Jonker, MD (1) · James Burke, MD (1) · Karen Kelly (1)
PMID 21699798, PMID 22019520, PMID 24063735, PMID 24586226, PMID 24657484, PMID 26727163, PMID 28177438, PMID 28923084, PMID 37506588, PMID 39060022, PMID 42744798
2014 (1), 2015 (1), 2025 (1), P30CA093373 (1)